PHOSPHOLIPID AUTOANTIBODIES: TIME FOR A NEW IMMUNO-ASSAY?

REFERENCES

• Harris E. N. Antiphospholipid Syndrome. Rheumatology, J. H. Kippel. Mosby, LondonUK 1998; Vol. 7: 35, 2nd Ed.
   Google Scholar
• Petri M. Pathogenesis and Treatment of the Antiphospholipid Antibody Syndrome. Med. Clin. North Am. 1997; 81: 151–177
   PubMed Web of Science ®Google Scholar
• Harris E. N. Special report. The Second International Antiticardiolipin Standardization Workshop/The Kingston Antiphosphopholipid Antibody Study (KAPS) Group. Am. J. Clin. Pathol. 1990; 94: 476–484
   PubMed Web of Science ®Google Scholar
• Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin Antibodies: Detection by Radioimmunoassay and Association with Thrombosis in Systemic Lupus Erythemathosus. Lancet 1983; 2: 1211–1214
   PubMed Web of Science ®Google Scholar
• Brandt J. T., Triplett D. A., Alving B., Scharrer I. Criteria for the Diagnosis of Lupus Anticoagulant. On Behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid of Scientific and Standardardization. Committee of the ISTH. An Update. Thromb. Haemost. 1995; 74: 1185–1190
   PubMed Web of Science ®Google Scholar
• Khamashta M. A., Hughes G. R. Antiphospholipid Antibodies and Antiphospholipid Syndrome. Curr. Opin. Rheumatol. 1995; 7(5)389–394
   PubMedGoogle Scholar
• Roubey R. A. Antiphospholipid Syndrome: Antibodies and Antigens. Curr. Opin. Hematol. 2000; 7(5)316–320
   PubMed Web of Science ®Google Scholar
• Rote N. S., Dostal-Johnson D., Branch W. D. Antiphospholipid Antibodies and Recurrent Pregnancy Loss: Correlation Between the Activated Partial Thromboplastin Time and Antibodies Against Phosphatidylserine and Cardiolipin. Am. J. Obstet. Gynecol. 1990; 163: 575–584
   PubMed Web of Science ®Google Scholar
• Merkel P. A., Chang Y., Pietrangeli S. S., Harris E. N., Polisson R. P. Comparison Between the Standard Anticardiolipin Antibody Test and a New Phospholipid Test in Patients with Connective Tissue Diseases. J. Rheumatol. 1999; 26(3)591–596
   PubMed Web of Science ®Google Scholar
• Horbach D. A., van Oort E., Donders R.C.J. M., Derkesen R. H., de Groot P. G. Lupus Anticoagulant is the Strongest Risk Factor for Both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus. Comparison Between Different Assays for the Detection of Antiphospholipid Antibodies. Thromb. Haemost. 1996; 76(6)916–924
   PubMed Web of Science ®Google Scholar
• Matsuura E., Igarashi M., Igarashi Y., Katahira T., Nagae H., Ichikawa K., Triplett D. A., Koike T. Molecular Studies on Phospholipid-Binding Sites and Cryptic Epitopes Appearing on Beta2-Glycoprotein I Structure Recognized by Anticardiolipin Antibodies. Lupus 1995; 4: 13–17
   Google Scholar
• El-Kadi H. S., Keil L. B., DeBari V. A. Analytical and Clinical Relationships Between Human IgG Autoantibodies to Beta 2 Glycoprotein I and Anticardiolipin Antibodies. J. Rheumatol. 1995; 22: 2233–2237
   PubMed Web of Science ®Google Scholar
• Montalban J., Rio J., Khamastha M., Davalos A., Codina M., Swana G. T., Calcagnotto M. E., Sumalla J., Mederer S., Gil A., Hughes G. R., Codina A. Value of Immunologic Testing in Stroke Patients. A Prospective Multicenter Study. Stroke 1994; 25: 2412–2415
   Google Scholar
• Muir K. W., Squire J. B., Alwan W., Lees K. R. Anticardiolipin Antibodies in an Unselected Stroke Population. Lancet 1994; 13(344)452–456
   Google Scholar
• Chakravarty K. K., Byron M. A., Webley M., Durkin C. J., Al-Hillawi A. H., Bodley R., Wozniak J. Antibodies to Cardiolipin in Stroke: Association with Mortality and Functional Recovery in Patients without Systemic Lupus Erythematosus. Q. J. Med. 1991; 79: 397–405
   PubMedGoogle Scholar
• Metz L. M., Edworthy S., Mydlarsky R., Fritzler M. J. The Frequency of Phospholipid Antibodies in an Unselected Stroke Population. Can. J. Neurol. Sci. 1998; 25: 64–69
   PubMed Web of Science ®Google Scholar
• The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin Antibodies and the Risk of Recurrent Thrombo-Occlusive Events and Death. Neurology 1997; 48: 91–94
   PubMed Web of Science ®Google Scholar
• Carmelingo M., Casto L., Censori B., Drago G., Frigeni A., Ferraro B., Servalli M. C., Radice E., Mamoli A. Anticardiolipin Antibodies in Acute Non-Hemorrhagic Stroke Seen Within Six Hours After Onset. Acta. Neurol. Scand. 1995; 92(1)69–71
   PubMed Web of Science ®Google Scholar
• Thurim S., Rand J. H., Wu X-X., Weinberger J., Horowitz D. R., Goldman M. E., Godbold J. H. Elevated Anticardiolipin Antibody Titer is a Stroke Risk Factor in a Multiethnic Population Independent of Isotype or Degree of Positivity. Stroke 1999; 30: 1561–1565
   PubMed Web of Science ®Google Scholar
• Levine S. R., Salowich-Palm L., Sawaya K. L., Perry M., Spencer H. J., Winkler H. J., Alam Z., Carey J. L. IgG Anticardiolipin Antibody Titer >40 GPL and the Risk of Subsequent Thrombo-Occlusive Events and Death. A Prospective Cohort Study. Stroke 1997; 1660–1665
   Google Scholar
• Ginsburg K. S., Liang M. H., Newcomer L., Goldhaber S. Z., Schur P. H., Hennekens C. H., Stampfer M. J. Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis. Ann. Intern. Med. 1992; 997–1002
   PubMed Web of Science ®Google Scholar
• Ahmed E., Stegmayr B., Trifunovic J., Weinehall L., Hallmans G., Lefvert A. K. Anticardiolipin Antibodies are not an Independent Risk Factor for Stroke: An Incident Case-Referent Study Nested Within the MONICA and Vasterbotten Cohort Project. Stroke 2000; 31: 1289–1293
   PubMed Web of Science ®Google Scholar
• Sletness K. E., Smith P., Abdelnoor M., Arnesen H., Wisloff F. Antiphospholipid Antibodies After Myocardial Infarction and Their Relation to Mortality, Reinfarction, and Non-Haemorrhagic Stroke. Lancet. 1992; 339: 451–453
   PubMed Web of Science ®Google Scholar
• Toschi V., Motta A., Castelli C., Paracchini M. L., Zerbi D., Gibelli A. High Prevalence of Antiphosphatidylinositol Antibodies in Young Patients with Cerebral Ischemia of Undetermined Cause. Stroke 1998; 29(9)1759–1764
   PubMed Web of Science ®Google Scholar
• Toschi V., Motta A., Castelli C., Gibelli S., Cimminiello C., Molaro G. L., Gibelli A. Prevalence and Clinical Significance of Antiphospholipid Antibodies to Noncardiolipin Antigens in Systemic Lupus Erythematosus. Haemostasis. 1993; 275–283
   PubMedGoogle Scholar
• Tuhrim S., Rand J. H., Wu X., Horowitz D. R., Weinberger J., Goldman M. E., Goldbold J. H. Antiphosphatidyl Serine Antibodies are Independently Associated with Ischemic Stroke. Neurology 1999; 53: 1523–1527
   PubMed Web of Science ®Google Scholar
• Tanne D., Triplett A. D., Levine S. L. Antiphospholipid-Protein Antibodies and Ischemic Stroke. Not Just Cardiolipin Any More. Stroke 1998; 29: 1755–1758
   PubMed Web of Science ®Google Scholar
• Cabral A. R., Amigo M. C., Cabiedes C., Alarcon-Seovia D. The Antiphospholipid/Cofactor Syndromes: A Primary Variant with Antibodies to Beta 2-Glycoprotein-I But No Antibodies Detectable in Standard Antiphospholipid Assays. Am. J. Med. 1996; 101: 472–481.
   PubMed Web of Science ®Google Scholar